Zim Laboratories Hits New 52-Week Low at Rs. 68.05

Zim Laboratories, a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of Rs. 68.05 on October 17, 2025. This decline marks a significant downturn for the company, which has seen its stock price fall consistently over the past four days, resulting in a total drop of 5.16% during this period.
In terms of performance metrics, Zim Laboratories has underperformed its sector by 1.58% today. The stock is currently trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a prolonged period of weakness. Over the past year, the stock has experienced a substantial decline of 37.70%, contrasting sharply with the Sensex, which has gained 3.82% during the same timeframe.

The company's financial health has been under scrutiny, with a reported net sales decline of 12.3% and negative results for the last five consecutive quarters. The return on capital employed (ROCE) has also dipped to 7.99%, reflecting ongoing challenges in maintaining profitability. As Zim Laboratories navigates these financial hurdles, its market position remains precarious.